Skip to main content
EW logo

Edwards Lifesciences Corporation (EW) Stock: Price, Forecast & Analyst Target

Edwards Lifesciences Corporation (EW) — MoonshotScore 93/100 (Exceptional band), calculated Nov 18, 2026. Price $105.23 (-0.19%), as of the Nov 18, 2026 trading session; market cap $60.5B. Expected results Feb 9, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$105.23 −$0.20 (-0.19%) Market Cap $60.5B

Edwards Lifesciences Corporation · EW · NYSE · Healthcare · Medical - Devices

Research dated 2026-09-12: Edwards Lifesciences is a focused structural-heart device company whose revenue is led by transcatheter heart valves, with surgical valves and mitral and tricuspid therapies forming the rest of the reported segment mix. The case depends on whether newer catheter-based therapies can broaden growth while the dominant valve franchise and strong balance sheet continue funding heavy research and commercial investment.

Price as of Nov 18, 2026

Key Statistics

93 of 100

MoonshotScore v2 · Edwards Lifesciences (EW)

Exceptional
Business Quality Elite (89)
Financial Safety Fortress (95)
Valuation Rich (39)
Growth Durability Compounding (88)
Momentum Surging (89)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, a fortress balance sheet and elite growth, but an expensive valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Compounding; Momentum: Surging.

  • EPS beat 7 of the last 8 reports
  • expected results Feb 9, 2027
  • Altman Z 14.22 · Piotroski F 8

Helping: business quality, balance-sheet strength, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for EW (57 recorded, newest six shown)
RecordedScoreBand
93Exceptional
93Exceptional
93Exceptional
93Exceptional
93Exceptional
93Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$105.23
Change on the day-0.19%
52-week range$74.66–$108.00
Market capitalisation$60.5B—
Price / earnings (trailing)59.56
Shares traded on the day3.92M
Beta (volatility vs the S&P 500)0.83

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $75, high $107, latest $105. 4 reported quarters marked, 3 above and 1 below the recorded estimate. $107 $75 high $107 Feb 10, 2026 · Earnings results · reported below the recorded estimate · close $761Apr 23, 2026 · Earnings results · reported above the recorded estimate · close $842Jul 23, 2026 · Earnings results · reported above the recorded estimate · close $833Nov 4, 2026 · Earnings results · reported above the recorded estimate · close $1024 Oct 17, 2025 Nov 18, 2026 · $105 $75Oct 17, 2025$82Oct 31, 2025$86Nov 14, 2025$87Nov 28, 2025$83Dec 12, 2025$87Dec 26, 2025$85Jan 9, 2026$84Jan 23, 2026$79Feb 6, 2026$80Feb 20, 2026$82Mar 6, 2026$83Mar 20, 2026$81Apr 2, 2026$81Apr 17, 2026$84May 1, 2026$81May 15, 2026$86May 29, 2026$85Jun 12, 2026$91Jun 26, 2026$92Jul 10, 2026$83Jul 24, 2026$90Aug 7, 2026$90Aug 21, 2026$90Sep 4, 2026$88Sep 18, 2026$85Oct 2, 2026$87Oct 16, 2026$92Oct 30, 2026$107Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Edwards Lifesciences (EW): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Strong
Financial Safety Strong
Valuation Weak
Growth Durability Strong
Momentum Strong

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Moderate
Revenue Growth Moderate
Debt/Equity Strong
ROE Neutral
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company less favourably than the MoonshotScore does: Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Edwards Lifesciences (EW), and what does it report?

Short answer · as of

Edwards sells replacement and repair technologies used by hospitals to treat structural heart disease, including minimally invasive valve systems, surgical tissue valves, and PASCAL and Cardioband therapies for mitral and tricuspid disease.

It reaches healthcare providers through its own sales force and independent distributors, so demand ultimately reflects procedure adoption rather than consumer purchasing.

Reported revenue is concentrated in transcatheter heart valves, with surgical heart valve therapy and transcatheter mitral and tricuspid therapies presented separately. Edwards is therefore better understood as a portfolio of valve-procedure franchises than as a general medical-device supplier.

2 · Latest results

What do the latest results show for Edwards Lifesciences (EW)?

Revenue, gross profit and operating profit rose from the preceding period, but net income and diluted earnings fell. Higher research and selling, general and administrative spending absorbed most of the gross-profit increase, while the latest earnings release still exceeded estimates for revenue and earnings.

Management separately warned that foreign exchange flowing through hedges should keep gross margin near the low end of its prior range. It nevertheless expects operating margin near the high end of prior guidance, implying that expense discipline and mix must offset the gross-margin drag if that outlook is to hold.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$1.72B Nov 4, 2026
Latest report · revenue estimate
$1.68B Nov 4, 2026
Latest report · revenue vs estimate
Above estimate Nov 4, 2026
Latest report · EPS vs estimate
Above estimate Nov 4, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 4, 2026$1.72B$1.68B$0.8000$0.7440
Jul 23, 2026$1.74B$1.70B$0.7800$0.7430
Apr 23, 2026$1.65B$1.60B$0.7800$0.7290
Feb 10, 2026$1.57B$1.55B$0.5800$0.6180
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$1.55B$291M$0.50 (diluted)
Q4 FY2025$1.57B$91M$0.16 (diluted)
Q1 FY2026$1.65B$381M$0.66 (diluted)
Q2 FY2026$1.74B$242M$0.42 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Edwards Lifesciences (EW)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Cash and short-term investments exceed total debt by a wide margin, liquidity ratios are high, and the distress screen indicates ample financial capacity. Operating cash flow has been positive throughout most of the recent series despite pronounced swings, and the latest inflow comfortably covered capital spending.

The operating risk is concentration, not near-term financing: transcatheter heart valves provide most reported segment revenue. A slowdown in procedures or adoption within that franchise would land on the largest revenue pool, while foreign-exchange pressure is already present in management’s margin outlook.

4 · What to check next?

What should you watch next at Edwards Lifesciences (EW)?

Short answer · as of

The next earnings report is expected on Feb 9, 2027.

PASCAL is the clearest near-term operating marker. Management plans a domestic launch for tricuspid patients alongside a presentation of trial results; evidence of adoption would indicate whether the mitral and tricuspid franchise is beginning to carry more weight beside the much larger transcatheter valve business.

The scheduled earnings release warrants attention across revenue, gross margin, operating margin and cash conversion. Continued sales growth with operating margin holding up despite hedge-related pressure, plus operating cash flow comfortably above capital spending, would support the current pattern; deterioration across those measures would break it. Longer-range estimates also embed continued revenue and earnings expansion, raising the importance of adoption and margin execution.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Edwards Lifesciences compare with its peers?

Short answer

Edwards Lifesciences's score ranks tied for 2nd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Edwards differs from broad medical-device groups through its narrow structural-heart focus: catheter-delivered valves are the core, surgical valves remain meaningful, and mitral and tricuspid therapies are a smaller expansion platform. That concentration supports deep clinical and commercial specialization but leaves less internal diversification when the main valve franchise slows.

Research spending is large and persistent, while gross and operating margins remain substantial and net cash provides funding flexibility. The resulting profile is closer to a focused innovation franchise than a diversified hospital-supply company.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
argenx SE (ARGX) Named competitor$941.25 Nov 18, 2026$59.2B96 5-pillar Nov 18, 2026
Edwards Lifesciences (EW) — this page$105.23$60.5B93
DexCom, Inc. (DXCM) Same industry, near in market value$82.52 Nov 18, 2026$30.8B93 5-pillar Nov 18, 2026
Cardinal Health, Inc. (CAH) Named competitor$278.35 Nov 18, 2026$64.3B88 5-pillar Nov 18, 2026
STERIS plc (STE) Same industry, near in market value$259.57 Nov 18, 2026$25.2B87 5-pillar Nov 18, 2026
Smith & Nephew plc (SNN) Same industry, near in market value$30.32 Nov 18, 2026$12.7B84 5-pillar Nov 18, 2026
Medtronic plc (MDT) Same industry, near in market value$100.72 Nov 18, 2026$129B81 5-pillar Nov 18, 2026
Alcon Inc. (ALC) Named competitor$75.23 Nov 18, 2026$36.1B80 5-pillar Nov 18, 2026
Stryker Corporation (SYK) Same industry, near in market value$318.15 Nov 18, 2026$121B80 5-pillar Nov 18, 2026
Zimmer Biomet Holdings, Inc. (ZBH) Same industry, near in market value$103.32 Nov 18, 2026$19.6B79 5-pillar Nov 18, 2026
Koninklijke Philips N.V. (PHG) Same industry, near in market value$29.81 Nov 18, 2026$29.1B78 5-pillar Nov 18, 2026
Boston Scientific Corporation (BSX) Same industry, near in market value$43.64 Nov 18, 2026$63.3B77 5-pillar Nov 18, 2026
Haleon plc (HLN) Named competitor$9.08 Nov 18, 2026$39.8B75 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$100.00 – $120.00
Consensus target
$108.70
Median target
$110.00

Consensus record · Captured .

Measured against a quoted price of $105.23 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 13, 2026

Transactions
53
Identified insiders
8
Purchases
0
Sales
20
Other transactions
33

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held EW in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.15%$35.22MAdded +48.2% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Edwards Lifesciences (EW)?

Read these with our analysis →

Common Questions About EW (Healthcare)

The last 2 questions are answered from this page's own dated data, not from the research.

What does Edwards Lifesciences sell through its transcatheter heart valve franchise?

It supplies minimally invasive valve-replacement systems to healthcare providers. Because this franchise supplies most reported segment revenue, procedure adoption here has the greatest influence on companywide sales.

Why is PASCAL important to Edwards Lifesciences?

PASCAL extends Edwards beyond its core transcatheter valve-replacement franchise into mitral and tricuspid therapy. Management has tied the program’s near-term progress to a domestic tricuspid launch and a trial-results presentation.

Can Edwards Lifesciences expand operating margin while gross margin is pressured by currency hedges?

Management’s outlook pairs lower-end gross-margin expectations caused by foreign exchange through hedging with upper-end operating-margin expectations. Delivery therefore requires sufficient operating leverage or spending control below gross profit to absorb that pressure.

How exposed is Edwards Lifesciences to transcatheter heart valve demand?

That franchise is the largest reported revenue pool by far, ahead of surgical valves and mitral and tricuspid therapies. Demand weakness there would be difficult for the smaller franchises to offset over a short period.

What is the EW stock price today?

The last price recorded for Edwards Lifesciences Corporation (EW), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the EW price target?

The analyst consensus price target for Edwards Lifesciences Corporation (EW), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 41 figures on this page — 34 from Financial Modeling Prep (FMP), 4 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Annual revenue and net result (USD millions); Cash, investments and debt
  • 1. What is Edwards Lifesciences (EW), and what does it report?: Business description; Revenue by segment
  • 2. What do the latest results show for Edwards Lifesciences (EW)?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts; Trailing twelve-month ratio set
  • 3. What are the financial strengths and risks for Edwards Lifesciences (EW)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash against market value; Trailing twelve-month ratio set; Distress and quality screens; Operating cash flow by quarter (USD millions); Revenue by segment; Management outlook — dated call excerpts
  • 4. What should you watch next at Edwards Lifesciences (EW)?: Management outlook — dated call excerpts; Next earnings report; Analyst revenue and earnings estimates (average); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Revenue by segment
  • 5. How does Edwards Lifesciences compare with its peers?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Trailing twelve-month ratio set; Cash, investments and debt
  • FAQ: What does Edwards Lifesciences sell through its transcatheter heart valve franchise?: Business description; Revenue by segment
  • FAQ: Why is PASCAL important to Edwards Lifesciences?: Business description; Revenue by segment; Management outlook — dated call excerpts
  • FAQ: Can Edwards Lifesciences expand operating margin while gross margin is pressured by currency hedges?: Management outlook — dated call excerpts; Quarterly income statement (USD thousands); Trailing twelve-month ratio set
  • FAQ: How exposed is Edwards Lifesciences to transcatheter heart valve demand?: Revenue by segment; Annual revenue and net result (USD millions)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold EW

Funds in our ETF coverage that list EW among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
SMI 3Fourteen Full-Cycle Trend ETF (FCTE)5.26%
FFLS ETF3.76%